DGIdb - ERCC1 Gene Record

ERCC1 2067 Clinically Actionable

Alternate Names:

2067
ERCC EXCISION REPAIR 1, ENDONUCLEASE NON-CATALYTIC SUBUNIT
ERCC1
COFS4
RAD10
UV20
126380
3433
ENSG00000012061
OTTHUMG00000182121
P07992
ERCC1_HUMAN
PA155
excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)
1735

Gene Info:

Is VIP	false
Has Variant Annotation	true
Gene Biotype	PROTEIN_CODING

(3 More Sources)

Gene Categories: Category Details

TRANSCRIPTION FACTOR COMPLEX
DNA REPAIR
TRANSCRIPTION FACTOR BINDING
CLINICALLY ACTIONABLE

Publications:

Yokoi M et al., 2018, Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy., Support Care Cancer
Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
Li et al., Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line., Anticancer Res.
Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
Rumiato E et al., 2013, ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy., Pharmacogenet Genomics
Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.
Usanova et al., 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression., Mol. Cancer
Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene
Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis
Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Cheng L et al., 2017, Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression., Mol Carcinog
Fujishima et al., 1997, Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line., Oncol. Res.
Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J